(11 June 2025) Fosun International Limited (HKEX stock code: 00656) was recently notified by the renowned British finance magazine, Global Banking and Finance Review, that it has received three awards: “ESG & Sustainability Awards – Best Sustainable Development Company Asia 2025”, “CSR Awards – Best CSR Company Asia 2025”, and “Brand of the Year Awards – Holding Group Brand of the Year Asia 2025”. These accolades underscore the market’s recognition of Fosun’s exceptional performance in ESG strategy, corporate governance, social responsibility, environmental protection, information disclosure, and stakeholder engagement.

On June 5, Henlius (2696.HK) participated in the 2025 Jefferies Global Healthcare Conference. As one of the most influential investment summits in the global life sciences industry, the event brought together over 3,000 leading executives, institutional investors, private equity investors and venture capitals to discuss current global trends and opportunities across the healthcare sector.

The updated data of efficacy and safety of Luvometinib (FCN-159), a self-developed innovative drug by Fosun Pharma, in pediatric participants with neurofibromatosis type 1 from a phase 2 study was presented in the American Society of Clinical Oncology (ASCO) Annual Meeting on May 22, 2025.

Shanghai, China, June, 3, 2025 – Shanghai Henlius Biotech, Inc. (2696. HK) announced the first release of results from the phase 1 clinical trial of HLX43, a PD-L1-targeting antibody-drug conjugate (ADC), for the treatment of advanced or metastatic solid tumors at the 2025 ASCO Annual Meeting. The leading principal investigator of this study is Jie Wang from the Cancer Hospital Chinese Academy of Medical Sciences. Leveraging on the precise molecular design and multiple innovative mechanisms, HLX43 has demonstrated superior anti-tumor activity with a manageable safety profile in patients with advanced/metastatic solid tumors. Particularly, encouraging preliminary efficacy was observed in non-small cell lung cancer (NSCLC) and thymic squamous cell carcinoma (TSCC) patients, demonstrating best-in-class potential for clinical development. At present, no PD-L1 targeting ADC has been approved for marketing globally. HLX43 may thus benefit more patients with advanced or metastatic solid tumors by providing a novel treatment option for those who are unresponsive or have developed resistance to PD-1/PD-L1-targeted therapies.

On June 2, 2025, Henlius (2696.HK) announced that the latest research results of novel anti-HER2 monoclonal antibody (mAb) HLX22 were presented at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting. These included updated efficacy and safety data with over two years of follow-up from the phase 2 clinical study (HLX22-GC-201) evaluating HLX22 in combination with trastuzumab and chemotherapy as a first-line treatment for HER2-positive advanced gastric cancer, as well as the debut of the study design for the international multicentre phase 3 clinical trial (HLX22-GC-301), which features a head-to-head comparison with the first-line standard of care therapy (trastuzumab + chemotherapy ± pembrolizumab).

Shanghai, China, June 1, 2025 - Shanghai Henlius Biotech, Inc. (2696.HK) announced that the latest results from over ten studies on lung and gastrointestinal cancer of Henlius’ self-developed innovative anti-PD-1 monoclonal antibody (mAb) HANSIZHUANG (serplulimab, trade name: Hetronifly^® in Europe) were presented at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting. HANSIZHUANG is the first anti-PD-1 mAb for the first-line treatment of SCLC and has been approved in over 30 countries and regions including China, Europe and Southeast Asia.

(May 29, 2025, Shanghai, China) — On 29 May, 2025, Shanghai Fosun Pharmaceutical (Group) Co., Ltd. (“Fosun Pharma”; Stock Code: 600196.SH, 02196.HK), announced that its self-developed innovative drug Luvometinib Tablets (Chinese trade name:复迈宁^®, project no.: FCN-159, the “New Drug”) has been officially approved for marketing by the National Medical Products Administration (NMPA). As a highly selective MEK1/2 inhibitor, the approved indication is the treatment of adult patients with Langerhans cell histiocytosis (LCH) and histiocytic neoplasms and the treatment of pediatric patients 2 years of age and older with neurofibromatosis type 1 (NF1) who have symptomatic plexiform neurofibromas (PN) not amenable to complete resection. The approval of the New Drug addresses unmet treatment needs in rare tumors and provides new treatment options for patients.

Shanghai, China, May 26, 2025 - Shanghai Henlius Biotech, Inc. (2696.HK) announced that the European Commission (EC) has granted Orphan Drug Designation (ODD) for HLX22, the company's innovative anti-HER2 monoclonal antibody (mAb) for the treatment of gastric cancer. At present, HLX22 is the world's first anti-HER2-targeted therapy to receive ODD approvals from both the FDA and the EC, suggesting its significant therapeutic potential in the treatment of gastric cancer.

Shanghai, China, May 14, 2025 - Shanghai Henlius Biotech, Inc. (2696.HK) announced that it has been included in the MSCI Global Small Cap Indexes following the results of the MSCI Equity Indexes May 2025 Index Review. The inclusion will be implemented as of the close of May 30, 2025.